Evi-1 Activators
The chemical class of Evi-1 activators comprises a diverse array of compounds that can modulate the activity of Evi-1, a transcriptional regulator intricately involved in cellular processes. While these compounds do not directly bind to Evi-1, they exert their influence through complex cellular pathways, ultimately leading to enhanced Evi-1 expression and function. One group of Evi-1 activators includes compounds like ATRA and Thapsigargin. ATRA, a derivative of vitamin A, indirectly activates Evi-1 by modulating retinoic acid signaling, influencing cellular processes that positively impact Evi-1 expression. Thapsigargin, by inhibiting SERCA, disrupts calcium homeostasis, altering the cellular environment necessary for efficient Evi-1 expression and function. Inhibitors of specific kinases, exemplified by PD98059 targeting MEK1/2 and SB203580 inhibiting p38 MAPK, indirectly activate Evi-1 by disrupting signaling pathways crucial for Evi-1 regulation. These compounds impact the cellular environment, leading to enhanced Evi-1 expression and function.
Histone deacetylase (HDAC) inhibitors, including Trichostatin A and Valproic Acid, indirectly activate Evi-1 by modulating the acetylation status of histones. The alteration in chromatin landscape influences transcriptional regulation, promoting enhanced Evi-1 activity in cellular processes. Furthermore, compounds like Rapamycin and Prostaglandin E2 (PGE2) indirectly activate Evi-1 by influencing the mTOR and cAMP signaling pathways, respectively. These compounds impact the cellular environment, leading to enhanced Evi-1 expression and function. In summary, the Evi-1 activators represent a collection of compounds that modulate Evi-1 activity through diverse signaling pathways. Understanding the nuanced interactions of these compounds with cellular networks provides valuable insights into potential strategies for manipulating Evi-1 expression and function, contributing to the broader landscape of transcriptional regulation in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
ATRA is a derivative of vitamin A and indirectly activates Evi-1. By modulating retinoic acid signaling, ATRA influences cellular processes that impact Evi-1 expression and function. The activation of ATRA leads to changes in the cellular environment, promoting enhanced Evi-1 activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Bay 11-7082 is an inhibitor of the NF-κB pathway and indirectly activates Evi-1. By inhibiting NF-κB signaling, Bay 11-7082 disrupts the negative regulation exerted by NF-κB on Evi-1. This compound influences the cellular environment, leading to the activation of Evi-1 through the relief of inhibitory signals emanating from the NF-κB pathway. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased intracellular cAMP levels. It indirectly activates Evi-1 by modulating the cAMP/PKA signaling pathway. The elevation in cAMP levels influences cellular processes that positively impact Evi-1 expression and function. Forskolin acts as an indirect activator by altering the intracellular environment through cAMP-mediated signaling. | ||||||
Hesperidin | 520-26-3 | sc-205711 sc-205711A | 25 g 100 g | $80.00 $200.00 | 5 | |
Hesperidin is a flavonoid that indirectly activates Evi-1 by influencing the PI3K/AKT signaling pathway. By modulating PI3K/AKT signaling, hesperidin alters the cellular environment necessary for efficient Evi-1 expression and function. This compound acts as an indirect activator by promoting enhanced Evi-1 activity through the modulation of key proteins and downstream signaling events. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that indirectly activates Evi-1. By inhibiting the proteasome, MG-132 stabilizes proteins involved in Evi-1 regulation. This stabilization leads to enhanced expression and function of Evi-1 in cellular processes. MG-132 acts as an indirect activator by preventing the degradation of key regulatory proteins involved in Evi-1 signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK1/2, affecting the MAPK/ERK signaling pathway. It indirectly influences Evi-1 by disrupting MAPK/ERK-mediated events crucial for Evi-1 regulation. PD98059's impact on this pathway alters the cellular milieu, indirectly activating Evi-1 and promoting its enhanced expression and function in cellular processes. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $56.00 $156.00 $270.00 $665.00 | 37 | |
PGE2 is a lipid mediator and indirectly activates Evi-1. By modulating the cyclic AMP (cAMP) signaling pathway, PGE2 influences cellular processes that positively impact Evi-1 expression and function. This compound acts as an indirect activator by altering the intracellular environment through cAMP-mediated signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly activates Evi-1 by disrupting the mTOR signaling pathway. Through inhibition of mTOR, Rapamycin alters downstream signaling events, impacting cellular processes that regulate Evi-1 expression and function. This compound acts as an indirect activator by modulating the mTOR signaling cascade, leading to enhanced Evi-1 activity in cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK and indirectly activates Evi-1. By inhibiting p38 MAPK, SB203580 disrupts the negative regulation exerted by p38 MAPK on Evi-1. This compound influences the cellular environment, leading to the activation of Evi-1 through the relief of inhibitory signals emanating from the p38 MAPK pathway. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a potent inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) and indirectly activates Evi-1. By inhibiting SERCA, thapsigargin disrupts calcium homeostasis, leading to changes in the cellular environment that impact Evi-1 expression and function. This compound acts as an indirect activator by modulating intracellular calcium levels and downstream signaling events. | ||||||